Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
← catalyst calendarSponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
20estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-22 | actual | When the study began enrolling |
| Primary completion | 2026-05-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-15 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Hodgkin's Lymphoma Refractory/Relapsed
Interventions
- Drug: N803 — also filed as Anktiva
- Biological: CD19t-haNK suspension
- Drug: Cyclophosphamide — also filed as Cytoxan
- Drug: Fludarabine — also filed as Fludara
- Drug: Rituximab — also filed as Rituxan
Primary outcome
what the primary-completion date above is the date OFPrimary Outcome Measures
measured within 30 days after each cell infusion
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed